Oppenheimer: 3 stocks that can rise more than 100% from current levels
So far, September has been a wild ride of ups and downs. Following the recent bout of volatility, stocks have again ticked higher. But there remains uncertainty about another rescue program and presidential election, where does the market go from here? Weighing in for Oppenheimer, chief investment strategist John Stoltzfus argues that any market downturn appears “relatively implicit and systematic” and gives long-term investors “the chance to find infants who are in bathwater.” Went out together. ” He said, “For bewildered investors, the recent downdraft has presented an opportunity to make some profit without FOMO (fear of being exempted).” As for the tech heavyweight who has carried the market’s five-month charge, the strategist believes “current technology”. The stock will remain under pressure for some time seems exaggerated. “Stoltzfus says that” the technology stocks were not very rich in core value, given that developments in technology and innovation have yet to show signs of plateauing in the current cycle. ” In keeping with Stoltzfus’s approach, our focus shifted to stocks that were Oppenheimer. Analysts say. The firm’s professionals see the triple-digit upside potential in stores specifically for the three tickers. Running the names through TipRanks’ database, we wanted to find out what makes each one so compelling. MediWound Limited (MDWD) is developing state-of-the-art products, MediWound seeks to address unfamiliar needs in the field of severe burns and chronic wound management. With an important contract for safe government, Oppenheimer has high hopes for the name. In January, MDWD announced that the US Biomedical Advanced Research and Development Authority (BARADA) had entered into a contract for the $ 16.5 million purchase of NexBrid, designed to be removed. In adults with deep partial and full thickness thermal burns (a process called debris) for an emergency repository. According to management, the first delivery is scheduled for Q3 2020. In addition, the company filed a Nexobrid Biologics License Application (BLA) with the FDA in June to remove ascor in adults with deep partial-thickness and full-thickness thermal burns. . MDWD’s US commercial partner, Verikel, is preparing for an immediate launch upon approval. Endorsing Oppenheimer, 5-Star analyst Kevin Degator says that “given the filing of participation from three parties – against the backdrop of MDWD, US commercial partner VeriCell and funding partner at BARDA and the public sector work-for-home mandate Completed, we see the meeting deadline as a material milestone for MDWD’s shares and the derailment event … We believe Nexobrid is on track for a 1H21 launch. ” Should therapy eventually take place. Approved, MDWD is entitled to a $ 7.5 million milestone payment from Vericel. “We believe that the current cash from VCEL and the $ 7.5 million milestone payment upon Nexobrid approval must be operational in at least 2H23,” DeGetter said. Degator also says that MDWD supports plans to open 25 million sites in the US and Israel. Phase 2 study of EscharEx, its product for chronic wounds. Although COVID-19 was delayed, the analyst believes that “the current time period of 1H21 is attainable.” To this end, DeGeeter rated MDWD outperformed with a $ 7 price target. Should his thesis play out, a potential twelve-month gain of 117% could be in the cards. (To see DeGeeter’s track record, click here) All in all, other analysts echo DeGeeter’s sentiment. 4 buys and no hold or sell add to a strong buy consensus rating. The upside potential comes in at 106%, with an average price target of $ 6.63. (See MDWD Stock Analysis on TipRank) EuroGen Pharma (URGN) focuses primarily on Euro-oncology, EuroGen Pharma develops advanced non-surgical treatments to improve patients’ lives. As the launch of one of its products is progressing well, Oppenheimer believes it’s time to get on board. For the firm, analyst Leland Gershell points to UGN-101 as a key component of his rapid research. UGN-101, now formally launched in the US under the commercial name Jelmyto, was formulated as a treatment for low-grade upper tract urothelial carcinoma (LG UTUC). Analysts highlight that the launch of Juntimo is already a solid start, as eight patients received 20 doses of the drug in June. “Jellamito had sales of $ 371,000 in the first month of launch, but management commented on more than 100 urology exercises. The sites are ready for the product, and COVID-19 has not had an impact on that patient’s demand,” Gershel. Explained For good news, permanent C- and J-codes, which are expected in October and January 2021. Respectively, in Gershell’s opinion, can increase sales. According to Gelshell, the label can be updated to reflect full OLYMPUS data. It should be noted that patient and physician engagement may remain low through YE20, and restrictions around elective surgery may persist. He argues, he argues, that “LG UTUC’s lack of surgical urgency may interrupt treatment for several months, while Jeltio’s ability to administer in an outpatient setting may speed up treatment, favoring adoption.” . ” If that was not enough, the UGN-102. Its mitomycin gel that targets low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR-NMIBC) is set to enter conclusive testing before the end of 2020. Looking at previously released data, the therapy achieved a 65% complete response (CR after treatment initiation) three months. “To offset any potential COVID-19 effects on enrollment, URGN has increased the number of clinical trial sites outside of the U.S., in countries where there has not been a virus-related clinical delay,” Gerschel he said. Adding to all that, Gerschel commented, “We believe the price of Jellimeto and UGN-102 trade at a discount, and revenue growth over the next 12 months will support the stock.” To this end, Gerschel stands with the bull, repeating an outperform rating. At $ 48, his price target is upside by 123%. (To see Garshell’s track record, click here) What does Rest Street have to say? 3 Buy ratings and 1 Hold have been issued in the last three months. As a result, URGN receives a strong Buy consensus rating. In addition, an average price target of $ 44 reveals 104% upside potential. (See URGN stock analysis on TipRank) Ayala Pharmaceuticals Inc. (AILA) Last but not least we have Ayala Pharmaceuticals, which focuses on developing targeted therapies for cancer in which Notch activation is a known tumor driver. Based on progress in its growth pipeline, Oppenheimer sees large gains in store. Oppenheimer analyst Jay Olson believes ALA’s technology makes it a stand-out. Two of its candidates, AL101 and AL102, licensed from Bristol Myers, are gamma-secretase inhibitors that target increased activation of notch signaling in cancer cells. Any signaling plays an important role in normal cell development, and disturbances can cause lethal changes. . Olson commented, “We believe the Notch targeted therapies have promised to meet unmet clinical needs.” AYLA is building a bioinformatics database around Notch to better characterize and identify Notch-activated mutations. Additionally, at both the DNA and RNA levels, AYLA is collaborating with partners to develop diagnostic tests for NotL-activated mutations. We believe that these initiatives benefit LLAs by identifying respondents over the long term and expanding the addressable patient population. Despite the challenges presented by COVID-19, significant catalysts remain on track. The company is set to present new interim data from a Phase 2 ACCURACY open-label study of AL101 in ESMO’s Mini Oral Head and Neck Cancer section at R / M ACC. Given the available data, a recent cohort showed 69% DCR in a recent interim analysis. For the second cohort, it is evaluating a weekly dose of 6mg of AL101. “We consider the efficacy and safety data of the 6mg dose to be important for registration-enabling studies, and we estimate similar interim data readouts in 1H21,” Olson said, according to Good News, to the AYLA patient. Is on track to kill. Participation in the Phase 2 TENACITY Study of AL101 at R / M TNBC by YE20 after FDA approval by FDA in April. In 2021, AYLA plans to begin two additional Phase 2 studies, including AL102 for AL / R101, and AL101 for R / r T-ALL. “SpringWorks Therapeutics recently announced completion of patient enrollment of enrogasestate’s Phase 3 NFI trial in desmoid tumors with topline. Data is expected mid-2021, providing a read-over to AYLA’s AL102 program Should, ”Olsen noted. All of the above, Olson protested, “We are encouraged to benefit from AALA along many dimensions, including our drug candidates, cancer indication selection.”, And focus on identifying not-activating mutations while developing a diagnosis. . Notch’s targeted approach to AYLA should address unmet clinical needs for patients with rare but aggressive cancers. “It is no surprise, then, that Olsen lived with the bull. For this purpose For, he held an outperform rating and $ 23 price target on the stock, with a 123% upside potential. (To see Olsen’s track record, click here) Given the consensus breakdown, 2 bues and 1 hold over the past three months Have been published. Therefore, AYLA gets a Moderate Buy consensus rating. Based on the $ 19.83 average price target, shares may climb 92% higher over the next year. (See Ayala Stock Analysis at TipRank) Stock trading at attractive valuations To find good ideas for, buy TipRank’s Best Stocks, launch a new A tool that unites all of TipRank’s equity insights. Disclaimer: The opinions expressed in this article are solely those of select analysts. Content is to be used for informational purposes only. It is very important to do your own analysis before making any investment.